Daiwa Securities Group revised its price objective for Eli Lilly. Accelerating operational performance and strong demand for core products drive the adjustment.
The new target reflects confidence in durable earnings. High margins and successful therapy adoption bolster these earnings.
The development pipeline covers metabolic disorders, oncology, immunology, and neuroscience. This pipeline supports positive market sentiment. The higher valuation increases stock sensitivity to execution continuity.